Related Experiment Video

Updated: Aug 5, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Use of insulin lispro in the outpatient management of ketonuria

M T Travaglini1, S K Garg, H P Chase

  • 1Department of Pharmacy, Children's Hospital, Denver, Colo, USA.

Archives of Pediatrics & Adolescent Medicine
|July 17, 1998
PubMed

Insights

Insulin lispro is as effective as regular insulin for managing ketonuria in children with diabetes at home. This study found no significant differences in insulin dosage or resolution time, showing insulin lispro is a viable outpatient treatment option.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Pharmacology

Background:

  • Ketonuria is a common complication in children with diabetes.
  • Effective outpatient management strategies are crucial to prevent hospitalizations.

Purpose of the Study:

  • To compare the efficacy of insulin lispro versus regular insulin.
  • To evaluate outpatient management of ketonuria in pediatric diabetes patients.

Main Methods:

  • Prospective analysis of telephone records for 75 children with ketonuria.
  • Outcomes assessed included successful home treatment episodes, insulin dosage, and time to ketonuria resolution.

Main Results:

  • No significant difference in supplemental insulin doses for moderate or large urine ketone values between insulin lispro and regular insulin groups (P>.05).
  • Time to resolution of ketonuria was not statistically different between the two insulin types (P>.05).
  • All attempted home treatments via telephone were successful, with no hospitalizations required.

Conclusions:

  • Insulin lispro demonstrates effectiveness as an alternative for outpatient management of ketonuria in children with diabetes.
  • These findings support the use of insulin lispro in home-based diabetes care for ketonuria.
Abstract

More Related Videos

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion07:30

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion

Published on: December 13, 2024

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...